Less than a month after disclosing the next step of its Phase II study with talabostat for leukemia - and days after winning an FDA grant for the drug - Point Therapeutics Inc. launched the most advanced trial yet with the compound, starting its Phase III program to test talabostat in metastatic non-small-cell lung cancer. (BioWorld Today) Read More
